Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo
Xianrong Zhang1, Joseph Tamasi, Xin Lu
1Department of Orthopaedic Surgery, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
While the epidermal growth factor receptor (EGFR)-mediated signaling pathway has been shown to have vital roles in many developmental and pathologic processes, its functions in the development and homeostasis of the skeletal system has been poorly defined. To address its in vivo role, we constructed transgenic and pharmacologic mouse models and used peripheral quantitative computed tomography (pQCT), micro-computed tomography (µCT) and histomorphometry to analyze their trabecular and cortical bone phenotypes. We initially deleted the EGFR in preosteoblasts/osteoblasts using a Cre/loxP system (Col-Cre Egfr(f/f)), but no bone phenotype was observed because of incomplete deletion of the Egfr genomic locus. To further reduce the remaining osteoblastic EGFR activity, we introduced an EGFR dominant-negative allele, Wa5, and generated Col-Cre Egfr(Wa5/f) mice. At 3 and 7 months of age, both male and female mice exhibited a remarkable decrease in tibial trabecular bone mass with abnormalities in trabecular number and thickness. Histologic analyses revealed decreases in osteoblast number and mineralization activity and an increase in osteoclast number. Significant increases in trabecular pattern factor and structural model index indicate that trabecular microarchitecture was altered. The femurs of these mice were shorter and smaller with reduced cortical area and periosteal perimeter. Moreover, colony-forming unit-fibroblast (CFU-F) assay indicates that these mice had fewer bone marrow mesenchymal stem cells and committed progenitors. Similarly, administration of an EGFR inhibitor into wild-type mice caused a significant reduction in trabecular bone volume. In contrast, Egfr(Dsk5/+) mice with a constitutively active EGFR allele displayed increases in trabecular and cortical bone content. Taken together, these data demonstrate that the EGFR signaling pathway is an important bone regulator and that it primarily plays an anabolic role in bone metabolism.
Insights
The epidermal growth factor receptor (EGFR) signaling pathway is crucial for bone health, promoting bone formation and regulating bone mass. Inhibiting EGFR reduces bone mass, while activating it increases bone density.
Area of Science:
- Bone biology
- Cell signaling
- Skeletal system development
Background:
- The epidermal growth factor receptor (EGFR) signaling pathway is essential in many biological processes but its role in skeletal homeostasis is unclear.
- Understanding EGFR's function in bone development and maintenance is critical for addressing bone diseases.
Purpose of the Study:
- To investigate the in vivo role of EGFR in skeletal development and homeostasis.
- To determine the specific contribution of EGFR signaling to bone metabolism and microarchitecture.
Main Methods:
- Generated transgenic mouse models with altered EGFR activity (knockout, dominant-negative, and constitutively active alleles).
- Utilized peripheral quantitative computed tomography (pQCT) and micro-computed tomography (µCT) for bone phenotyping.
- Conducted histomorphometry and colony-forming unit-fibroblast (CFU-F) assays to assess cellular and microarchitectural changes.
- Administered EGFR inhibitors to wild-type mice to evaluate pharmacologic effects.
Main Results:
- Reduced EGFR activity in osteoblasts led to decreased trabecular bone mass, altered microarchitecture, reduced osteoblast numbers, and increased osteoclast numbers.
- EGFR inhibition in wild-type mice significantly reduced trabecular bone volume.
- Mice with constitutively active EGFR showed increased trabecular and cortical bone.
- Bone marrow mesenchymal stem cell populations were reduced with diminished EGFR activity.
Conclusions:
- EGFR signaling is a critical regulator of bone metabolism, primarily exerting an anabolic effect.
- Targeting EGFR signaling represents a potential therapeutic strategy for modulating bone mass and treating skeletal disorders.
Related Concept Videos
Mitogens and the Cell Cycle
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
TGF - β Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Osteoclasts in Bone Remodeling
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
